DaVita Inc. (DVA)
- Previous Close
143.63 - Open
143.59 - Bid 143.33 x 1000
- Ask 143.76 x 800
- Day's Range
142.76 - 144.41 - 52 Week Range
131.44 - 179.60 - Volume
101,369 - Avg. Volume
999,088 - Market Cap (intraday)
11.028B - Beta (5Y Monthly) 1.14
- PE Ratio (TTM)
13.37 - EPS (TTM)
10.73 - Earnings Date May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
164.57
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
www.davita.com76,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: DVA
View More
Performance Overview: DVA
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DVA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DVA
View MoreValuation Measures
Market Cap
11.04B
Enterprise Value
22.26B
Trailing P/E
13.39
Forward P/E
13.02
PEG Ratio (5yr expected)
1.97
Price/Sales (ttm)
0.98
Price/Book (mrq)
91.15
Enterprise Value/Revenue
1.74
Enterprise Value/EBITDA
8.17
Financial Highlights
Profitability and Income Statement
Profit Margin
7.31%
Return on Assets (ttm)
7.15%
Return on Equity (ttm)
51.74%
Revenue (ttm)
12.82B
Net Income Avi to Common (ttm)
936.34M
Diluted EPS (ttm)
10.73
Balance Sheet and Cash Flow
Total Cash (mrq)
846M
Total Debt/Equity (mrq)
576.99%
Levered Free Cash Flow (ttm)
1.18B
Research Analysis: DVA
View MoreResearch Reports: DVA
View MoreRaising target price to $157.00
DAVITA INC has an Investment Rating of BUY; a target price of $157.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of High.
RatingPrice TargetRaising target price to $156.00
DAVITA INC has an Investment Rating of BUY; a target price of $156.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of High.
RatingPrice TargetLowering target price to $148.00
DAVITA INC has an Investment Rating of BUY; a target price of $148.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of High.
RatingPrice TargetRating increased to a BUY
DAVITA INC has an Investment Rating of BUY; a target price of $161.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice Target